CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 181 enrolled
Drug / intervention
Varenicline +2 moredrug
Likely dose
Varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04228965
NCT04228965Phase 4Completed

A Prospective Trial of Varenicline and Incentives for Tobacco Cessation in Adults

Medical University of South Carolina·interventional·Posted Jan 14, 2020·Updated Jun 15, 2025

In Brief

A Phase 4 clinical trial evaluating Varenicline, Contingency Management, and 1 other intervention for Tobacco Use Disorder. Completed, enrolled 181 participants across 3 sites.

Detailed Summary

The purpose of this study is to better understand tobacco outcomes using a well-known stop smoking medication, varenicline, and financial incentives with tobacco users. The investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive tobacco cessation treatment (varenicline) for 12 weeks. This study will recruit adult tobacco users (ages 18-40) who are motivated to quit smoking cigarettes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedJan 14, 2020
Enrollment StartJan 28, 2020
Primary CompletionJun 12, 2024
Study CompletionSep 13, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.5 years ago

Interventions

Vareniclinedrug

Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.

Contingency Managementbehavioral

Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.

Counselingbehavioral

Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.